Tudorza pressair approved for COPD

July 24, 2012

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) in people 18 and older.

COPD, most often caused by smoking, encompasses chronic bronchitis and emphysema. Symptoms usually include , excessive phlegm and chest tightness, the FDA said in a news release.

The Tudorza Pressair inhaler, to be used twice daily, relaxes muscles around the lung's large airways, improving breathing. It is not meant to be used as a rescue inhaler during sudden asthma attacks, the agency said.

Common side effects observed during clinical testing included headache, nasal inflammation and cough.

The inhaler is distributed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.

Explore further: Researchers question safety of mist inhalers for delivering common drug for chronic lung disease

More information: Medline Plus has details about COPD.

Related Stories

Beta blockers may help COPD sufferers

May 12, 2011

(Medical Xpress) -- Beta blockers, the group of drugs commonly prescribed to patients with heart diseases, may also have considerable benefits for sufferers of diseases such as chronic bronchitis and emphysema, according ...

FDA phases out inhaler due to environmental impact

September 22, 2011

(AP) -- Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government's latest attempt to protect the Earth's atmosphere.

Recommended for you

Zika virus infection alters human and viral RNA

October 20, 2016

Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications—chemical tags known as ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.